Wird geladen...

Should elderly patients with higher-risk myelodysplastic syndromes undergo allogeneic hematopoietic stem cell transplantation?

Myelodysplastic syndromes (MDS) include a group of hematopoietic malignancies characterized by dysplastic changes, ineffective hematopoiesis and variable risk of leukemic progression. At diagnosis, 86% of MDS patients are ≥60 years. Azacitidine, the only drug that prolongs life in high-risk (HR)-MDS...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Zeidan, Amer M, Gore, Steven D
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2013
Schlagworte:
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4124615/
https://ncbi.nlm.nih.gov/pubmed/24093972
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1586/17474086.2013.827097
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!